|
Originally published In Press as doi:10.1074/jbc.M000145200 on May 2, 2000
J. Biol. Chem., Vol. 275, Issue 28, 21272-21277, July 14, 2000
NF-IL6 (C/EBP ) Vigorously Activates il1b Gene
Expression via a Spi-1 (PU.1) Protein-Protein Tether*
Zhiyong
Yang §,
Nawarat
Wara-aswapati ¶,
Changmin
Chen ,
Junichi
Tsukada **, and
Philip E.
Auron 
From The New England Baptist Bone & Joint Institute,
Division of Hematology and Oncology, Beth Israel Deaconess
Medical Center, Department of Medicine, Harvard Medical School,
Boston, Massachusetts 02115
Received for publication, January 10, 2000, and in revised form, May 2, 2000
 |
ABSTRACT |
Two classes of transcription factors, ETS and
bZIP, stand out as key mediators of monocyte commitment and
differentiation. The ETS domain factor Spi-1 (also called PU.1) and the
bZIP factor NF-IL6 (also called C/EBP ) have been shown to be
involved in the transcriptional regulation of interleukin-1 gene
(il1b) and other monocyte-specific genes. We now show that
these two factors strongly cooperate on the il1b core
promoter ( 59/+12) in the absence of direct NF-IL6 binding to DNA.
Transient transfection assays, using mutated il1b core
promoters, showed that the Spi-1, but not the NF-IL6, binding site is
absolutely required for functional cooperativity. Furthermore, the
NF-IL6 transactivation domain (TAD) is functionally indispensable and
more critical than that of Spi-1. Additionally, TAD-deficient NF-IL6
functions as a dominant negative for Spi-1-mediated activation,
suggesting the involvement of the bZIP DNA binding domain. This is
supported by the demonstration of in vitro interaction
between the NF-IL6 bZIP and Spi-1 winged helix-turn-helix (wHTH) DNA
binding domains, arguing that NF-IL6 vigorously activates the
il1b core promoter via protein-tethered transactivation
mediated by Spi-1.
 |
INTRODUCTION |
Myeloid lineage differentiation and the expression of activated
monocyte/macrophage genes, such as the gene encoding interleukin 1
(IL-1 ),1 depend upon the
activity of at least two key transcriptional regulatory factors. One of
these is NF-IL6 (also called C/EBP , NF-M, AGP/EBP, LAP, IL6-DBP, and
CRP2) (1-6), which is constitutively expressed in resting monocytes
and immediately activated by translocation from cytoplasm to nucleus by
agents such as lipopolysaccharide, phorbol myristate acetate (PMA), and
IL-6. NF-IL6 is a bZIP transcription factor that belongs to the C/EBP
family of proteins (1, 3, 7). Recent studies have shown that NF-IL6 is
capable of synergistically cooperating with other transcription
factors, including NF- B (8), Sp1 (9), and GATA-1 (10). In these
cases, the binding of NF-IL6 and its partners to their recognition
sites in the promoters is required for the functional cooperativity. A
second factor, Spi-1/PU.1, is a winged helix-turn-helix (wHTH)
transcription factor that belongs to the ETS family of proteins. Spi-1
expression is primarily restricted to myeloid cells, whereas NF-IL6 is
more broadly expressed. The importance of C/EBP factors and Spi-1 in myeloid cells emphasizes the need to understand the mechanisms regulating their functions.
IL-1 is an important inflammatory and immunoregulatory cytokine
expressed by primarily activated monocytes/macrophages in response to a
variety of stimuli, including lipopolysaccharide, PMA, IL-1 ,
and other cytokines (11). Uncovering the mechanisms that drive the
expression of il1b will elucidate the events of normal
myeloid commitment and differentiation as well as the dysregulation of
gene expression that leads to inflammatory diseases. Zhang and Rom (12)
reported that the 131/+12 il1b promoter contained two
NF-IL6 binding elements, located at positions 90/ 82 and 41/ 33.
While the importance of the more upstream NF-IL6 site has been
established (13), the function of the 41/ 33 is poorly defined. This
site overlaps the 3'-end of a Spi-1 binding site at 50/ 39 by 3 base
pairs. It was shown that in lipopolysaccharide-simulated macrophage
cells, Spi-1, but not NF-IL6, is a predominant protein factor bound to
this overlapping sequence (13, 14) in the 59/+12 il1b core
promoter. These data argue that the Spi-1, but not the overlapping
NF-IL6 binding element, is required for maximal activation of the
il1b core promoter.
There are accumulating evidence showing that Spi-1 and C/EBP family
factors are important for the regulation of many genes involved in
immunity and hematopoiesis, such as macrophage colony-stimulating factor receptor (15) and neutrophil elastase (16), in addition to the
IL-1 gene. However, the mechanism responsible for the functional
cooperativity is still poorly understood. Many ETS target sites are
found adjacent to binding sites for other protein factors, which appear
to functionally cooperate. The most frequently reported type of
composite site involves cooperative interactions between ETS proteins
and bZIP factors (17, 18), such as the interaction between the Spi-1
wHTH ETS DNA binding domain and the NF-IL6 (C/EBP ) leucine zipper
region (17). In transient expression assays, using an artificial
promoter containing adjacent Spi-1 and NF-IL6 sites, Nagulapalli
et al. (17) observed that Spi-1 and NF-IL6 could
functionally cooperate to activate transcription. However, the combined
roles of NF-IL6 and Spi-1 in naturally occurring promoters have not
yet been reported. In most cases, the association of another factor
with Spi-1 results in strong synergistic activation of target gene. A
recent example is c-Jun, which acts as a Spi-1 coactivator on the
promoters of myeloid genes coding for macrophage scavenger receptor
(19), and macrophage colony-stimulating factor receptor (20).
The close proximity of the Spi-1 and the putative NF-IL6 sites does not
seem to be fortuitous. Even though the putative NF-IL6 site at
positions 41/ 33 seemed to not be critical as a transcription factor
binding site, as suggested by Buras' in vitro data (14), we
still investigated the possible functional involvement of NF-IL6 in the
regulation of the il1b core promoter. The study described here demonstrates that NF-IL6 strongly cooperates with Spi-1 to activate the il1b core promoter ( 59/+12), in which the
integrity of the Spi-1 binding site, but not the putative NF-IL6
binding site, is critical for the synergy. In addition, the functional cooperativity between Spi-1 and NF-IL6 definitely requires the transactivation domain (TAD) of NF-IL6, but not those of Spi-1. Spi-1
seems to act as an anchor, which tethers NF-IL6 to the il1b core promoter to exert activation, without NF-IL6 binding to its cognate binding site. This mechanism, which we have called
protein-tethered transactivation (PTT) (20, 21), may be more widely
used in gene activation than is presently appreciated.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
HeLa cells (Strain S3) were cultured in
Dulbecco's modified Eagle's medium containing 10% (v/v) fetal bovine
serum and 0.5% penicillin-streptomycin as described previously
(21).
Plasmid Constructions--
The human il1b core
promoter region ( 59/+12) and its mutants were generated by polymerase
chain reaction and inserted into pGL3-Basic vector (Promega) at
MluI and BglII sites to construct promoter-reporter plasmids. The pRc/CMV plasmids expressing wild-type Spi-1 and a series of Spi-1 deletion mutants were constructed as
described previously (21) (22). Expression vectors for the full-length
NF-IL6 (pcDNA3.1-NF-IL6) and a truncated NF-IL6 with an internal
deletion between the two SplI restriction sites (pcDNA1-NF-IL6 Spl) were constructed by inserting the
NF-IL6 cDNAs (23) into expression vectors pcDNA3.1 or
pcDNA1 (Invitrogen). GST fusion constructs containing various Spi-1
motifs were made as described previously (21). GST-NF-IL6,
GST-NF-IL6( spl), and GST-bZIP fusion protein expression
vectors were constructed by inserting full-length, truncated
Spl NF-IL6 coding region, and a polymerase chain
reaction-amplified fragment encoding the bZIP region of NF-IL6 from
amino acids 269-345, into pGEX-2T (Amersham Pharmacia Biotech) at
BamHI and EcoRI sites.
Transfections and Luciferase Assays--
HeLa S3 cells were
plated in 24-well plates 24 h before transfection. A total of 1.8 µg plasmid DNA, including 0.5 µg of reporter, 0.5 µg of each
expression vector, and 0.3 µg of pCMV·Sport- -gal (Life
Technologies, Inc.), except as noted, was transfected into the cells
using DOTAP transfection reagent (Roche Molecular Biochemicals GmbH) as
described previously (21). After incubation for 24 h, cells were
stimulated with 50 ng/ml PMA (Sigma) for 20 h. The cells were then
harvested and lysed in 150 µl of cell culture lysis reagent
(Promega). The lysates were assayed for luciferase activity using the
Promega luciferase assay kit.
Expression and Purification of GST Fusion
Protein--
Glutathione S-transferase fusion proteins were
prepared by standard procedures as described previously (21).
Equivalent amounts of GST fusion proteins (as determined by Bio-Rad and
confirmed by Coomassie Blue staining) were bound to 50 µl of
glutathione-Sepharose beads by incubation in a total volume of 500 µl
of NETN (20 mM Tris chloride, pH 8.0, 100 mM
NaCl, 1 mM EDTA, and 0.5% Nonidet P-40) (21) for 1 h
at 4 °C. The beads were washed three times in NETN buffer.
GST Fusion Protein Interaction Assays--
The Sepharose beads
bound with GST fusion protein were incubated with
35S-labeled in vitro translated protein (TNT T7
coupled reticulocyte lysate system, Promega) at 4 °C for 1 h.
The beads were washed five times in NETN buffer, and the bound proteins
were eluted by boiling for 5 min in SDS-PAGE loading buffer (50 mM Tris·Cl, pH 6.8, 30% glycerol, 0.4% SDS, and 0.1%
bromphenol blue) containing -mercaptoethanol. Proteins were analyzed
by SDS-PAGE (15% polyacrylamide gel), followed by soaking in Amplify
fluorographic reagent (Amersham Pharmacia Biotech) and exposed to Kodak
X-Omat film.
GST 1-Hybrid DNA Binding Assay--
A sensitive method modified
(21) from a technique previously reported by Chittenden et
al. (24) was used as to detect weak protein-DNA interaction.
Briefly, equivalent amounts of GST fusion proteins were bound to 50 µl of glutathione-Sepharose beads as described above. After washing
with NETN buffer three times, the beads were resuspended in 200 µl of
DNA probe binding buffer (20 mM HEPES, pH 8.0, 1 mM EDTA, 50 mM NaCl, 3 mM
MgCl2, 33 ng/µl poly(dI-dC), 1 mM
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride) and
incubated for 5 min at 4 °C. The beads were then incubated for 20 min at 4 °C with 200,000 cpm of 32P-labeled wild-type
probe corresponding to the il1b promoter sequence between
56 and 21 or the same probe with the putative NF-IL6 site mutated.
The beads were washed twice with the binding buffer containing 10 ng/ml
poly(dI-dC) and 0.5% Nonidet P-40. Specific binding was assessed by
Cerenkov counting of the protein-DNA complex on the
glutathione-Sepharose beads.
Electrophoretic Mobility Shift Assays--
Double-stranded
oligonucleotides spanning the overlapping Spi-1 and NF-IL6 sites
(il1b promoter region from 56 to 21) were synthesized
and labeled by using DNA polymerase Klenow fragment in the presence of
[ -32P]dATP and [ -32P]dGTP. EMSAs were
carried out by incubating 0.5 µl in vitro translated Spi-1
or NF-IL6 protein (TNT T7 coupled reticulocyte lysate system, Promega)
with 10,000 cpm of the wild-type il1b probe, or the probe carrying mutations in either the Spi-1 site or the NF-IL6 site, under
binding conditions of 10 mM Tris·Cl, pH 7.5, 50 mM NaCl, 3.3 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 5% glycerol with 1 µg of poly(dI-dC) in a final volume of 15 µl. The binding
reactions were performed on ice for 20 min and then subjected to
electrophoresis on 4% nondenaturing low ionic strength polyacrylamide
gels using 0.5 × TBE buffer (TBE, 45 mM Tris borate,
pH 8.3, and 1 mM EDTA). The gels were then dried and
analyzed by autoradiography.
 |
RESULTS |
NF-IL6 Strongly Cooperates with Spi-1 to Activate the ( 59/+12)
il1b Core Promoter--
We and others (12-14) have previously
reported that the 59/+12 il1b core promoter contains a
Spi-1 ( 50/ 39) and an NF-IL6 ( 41/ 33) binding site. To verify
that Spi-1 and NF-IL6 could transactivate the il1b core
promoter, we performed transient cotransfection assays. A luciferase
reporter plasmid containing the il1b core promoter was
cotransfected into Spi-1-deficient HeLa S3 cells (25) along with
plasmids either expressing Spi-1, NF-IL6, or both (Spi-1+NF-IL6). The
cells were stimulated with PMA 20 h before luciferase assays to
activate the NF-IL6 protein. As shown in Fig.
1, NF-IL6 alone only had a minimal
effect, whereas Spi-1 stimulated activity by about 20-fold. However,
NF-IL6 together with Spi-1 activated the il1b core promoter
by about 380-fold, suggesting a strong cooperativity between these two
factors.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of Spi-1and NF-IL6 on the
transcription of the wild-type or mutant il1b
promoter. The wild type il1b ( 59/+12) core
promoter-luciferase reporter plasmid, or reporter constructs containing
mutations of the Spi-1 and NF-IL6 sites, were transfected into HeLa S3
cells along with vectors expressing either Spi-1 or NF-IL6 as shown.
The luciferase reporter vector pGL3-Basic containing no insertion was
also cotransfected with various expression vectors as a control.
Luciferase activities were normalized to -galactosidase activities
expressed by a cotransfected plasmid. The level of the wild-type
reporter construct in the presence of empty expression vectors is set
to 1. Data represent the mean and the S.E. of three repetitions.
|
|
Mutation of the Spi-1 Site, but Not the NF-IL6 Site, Abolishes
Cooperative Activation--
To determine whether the cooperative
activation of the il1b core promoter by Spi-1 and NF-IL6
depends on their binding sites, site-directed mutagenesis was used to
introduce multiple nucleotide sequence substitutions into the Spi-1
(mut Spi-1), NF-IL6 (mut NF-IL6), or both
(mut both) binding sites, without changing the nucleotides
in the overlapping region (Fig. 2). In
agreement with previous studies (13), mutation of the Spi-1 binding
site completely prevented activation by Spi-1, either alone or with
NF-IL6 (Fig. 1). Transfection of NF-IL6 alone did not affect the
promoter activity, even when the overlapping Spi-1 site was disrupted.
A promoter containing an intact Spi-1 site and either an intact or
mutated NF-IL6 site (WT or mut NF-IL6) supported
activation by Spi-1 alone. Importantly, a promoter containing an intact
Spi-1, but a mutated NF-IL6 site (mut NF-IL6) retained a
majority of the synergistic activation in the presence of both Spi-1
and NF-IL6 (Fig. 1). Consequently, the Spi-1 binding site, but not the
NF-IL6 binding site, is critical for the cooperative transactivation of
this promoter by Spi-1 and NF-IL6.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 2.
Human il1b promoter
mutants. Shown are the locations and identities of mutations used
in this study (indicated by arrows). Numbering is relative
to the transcription initiation site. Sequences conforming to Spi-1 and
NF-IL6 consensus recognition sites are labeled.
|
|
Using the wild-type il1b probe, containing both the Spi-1
and NF-IL6 sites (Fig. 3A),
in vitro translated Spi-1 can bind avidly to the probe in
EMSA (lane 2), as suggested by previous reports (13, 14).
Mutations in the core Spi-1 recognition sequence (AGAA to CTAA)
abolished Spi-1 binding (lane 3). Due to the weak equilibrium binding observed by EMSA between NF-IL6 and the
il1b probe ( 56/ 21) (data not shown), we employed a
GST-1-hybrid assay, capable of detecting complexes with either low
affinity or high decay rates (21). Fig. 3B shows that a
GST-bZIP fusion protein containing the NF-IL6 bZIP DNA-binding domain
could bind to the wild-type probe about six times better than the
binding between GST control protein and the probe. As expected, the
substitution of 4 nucleotides in the NF-IL6 consensus region prevented
the probe from being recognized by NF-IL6.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
Mutations within the il1b
probe abolish protein binding by Spi-1 and NF-IL6.
A, unprogrammed rabbit reticulocyte lysate (lane
1) and in vitro translated Spi-1 (lanes 2 and 3) were incubated with the wild-type il1b
probe (between nucleotides 56 and 21) in EMSA. Also, in
vitro translated Spi-1 was incubated with the same probe
containing mutations in the core Spi-1 recognition site (AGAA to CTAA)
in EMSA (lane 3). B, the GST-1-hybrid assay was
used to detect weak protein-DNA interaction between NF-IL6 bZIP and the
il1b probe. GST and GST-bZIP fusion proteins immobilized on
glutathione-Sepharose were tested for DNA binding activity using either
wild type (wt) il1b probe (between nucleotides
56 and 21) or probe containing mutations in the putative NF-IL6
site (mNF-IL6). The results are the relative binding
affinity with the cpm of mNF-IL6 probe bound to GST-bZIP set as 1. Error bars represent the S.E. in results from three
repetitions.
|
|
The NF-IL6 TAD Is Indispensable for Functional Cooperativity, while
Spi-1 TADs Only Partly Contribute--
NF-IL6 is a 345-amino acid
protein with a COOH-terminal basic leucine zipper structure (bZIP) that
binds to DNA. The TAD of NF-IL6 has been reported to bind directly to
CBP/p300 (26). The extreme amino terminus of NF-IL6 is capable of
recruiting SWI/SNF chromatin-remodeling complex and activating
endogenous target genes in concert with the TAD (27). Between the TAD
and the bZIP domains reside regulatory domains, which are involved in
intramolecular interactions that inhibit transactivation and DNA
binding when NF-IL6 is not activated by phosphorylation (28, 29) (Fig.
4A). Spi-1 possesses a
COOH-terminal ETS wHTH domain that is involved in both DNA binding as
well as protein-protein interactions involving AP-1 family members,
NF-IL6 (C/EBP ), and other proteins (17, 18, 20, 30). The
amino-terminal 170 amino acids of Spi-1 contains three independent
transcriptional activation domains: a glutamine-rich (Q, where Q
indicates Gln) domain that can also bind to CBP/p300 (31); an
amino-terminal, TBP (TATA box-binding protein) binding domain (32); and
a PEST domain, involved in protein-protein interactions with the
lymphoid-specific coactivator NF-EM5/Pip/IRF-4 (33, 34) (Fig.
5A).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
NF-IL6 with a disrupted TAD cannot
functionally cooperate with Spi-1. A, schematic
representation of NF-IL6 protein structure. Functional domains,
including a regulatory region (Reg.) that inhibits the TAD
and bZIP domains via intramolecular interaction, are shown. Also shown
is the dominant negative NF-IL6 mutant
(NF-IL6 Spl). B, wild-type
il1b ( 59/+12)-luciferase reporter plasmid was transfected
into HeLa S3 cells in the presence of vectors expressing wild-type
Spi-1 plus either mutant or wild-type NF-IL6. Activities are presented
as in Fig. 1.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
NF-IL6 and Spi-1 cooperativity is
differentially affected by distinct regions of the Spi-1 protein.
A, schematic representation of Spi-1 showing previously
identified functional regions and the regions contained within various
expression vectors. B, Spi-1 expression vectors as depicted
in A were transiently transfected into HeLa S3 cells with
wild-type il1b ( 59/+12)-luciferase reporter plasmid, in
either the presence or absence of NF-IL6 expression vector. Activities
are presented as in Fig. 1.
|
|
To determine the domains of Spi-1 and NF-IL6 required for
transcriptional cooperativity, we assayed deletion mutations of both
proteins in transient transfection assays. First, vectors coding for
full-length NF-IL6 and a truncation ( Spl) that can bind
to DNA, but lacks the TAD and a portion of the regulatory region, were
co-expressed with full-length Spi-1 and assayed for il1b
core promoter reporter activity in HeLa cells. Western analysis showed
that both the full-length and the truncated NF-IL6
( Spl) were correctly expressed by the
transfected plasmids in HeLa cells (data not shown). The truncated
NF-IL6 could not synergize with Spi-1 (Fig. 4B). Unlike the
observations with NF-IL6, the Spi-1 mutant constructs (Fig. 5,
A and B) with deletions of either the Q domain
( PN), or the Q domain together with the NH2-terminal TBP
binding domain ( 100, NN) retained significant ability to cooperate with NF-IL6. Deletion of the PEST region increased Spi-1 activation of the il1b core promoter and its ability to
synergize with NF-IL6, arguing for its dispensability. We have
previously shown that expression of the various Spi-1 derivatives in
HeLa cells with these vectors yielded comparable levels of proteins capable of binding specifically to DNA (13).
Dominant Negative NF-IL6 Represses Spi-1-dependent
Activation of the il1b Core Promoter in HeLa Cells--
Previously we
have shown that the Spl truncated NF-IL6 could antagonize
NF-IL6-dependent activation (23) of the il1b
upstream inducible enhancer (UIS), by competing with the wild-type
endogenous NF-IL6 for a specific NF-IL6 binding site. We have
transfected this dominant negative NF-IL6 mutant into HeLa cells in
either the presence or absence of Spi-1. As shown in Fig.
6, Spi-1 alone activated the
il1b core promoter. Strikingly, cotransfection of the NF-IL6
dominant negative repressed the Spi-1-mediated activation in a
dose-dependent fashion, presumably by interfering with
endogenous NF-IL6 function. Cotransfection of 0.5 or 1 µg of
Spl NF-IL6 vector with a constant amount of Spi-1
expression plasmid (0.25 µg) revealed a 20 and 60% decrease of
Spi-1-induced activity, respectively. However, the small amount of
basal il1b core promoter activity was not affected by the
NF-IL6 dominant negative when Spi-1 was not present, even though NF-IL6
is known to be endogenously expressed in HeLa cells (35).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
Dominant negative NF-IL6 represses
Spi-1-mediated activation of the il1b ( 59/+12) core
promoter. HeLa S3 cells were transfected with 0.25 µg of
il1b ( 59/+12)-luciferase reporter construct, 0.25 µg of
pRc/CMV vectors (with or without Spi-1 insert), together with the
indicated amount of plasmid expressing the dominant negative mutant of
NF-IL6 (NF-IL6 Sp1). Each well was also
transfected with 0.15 µg of a -galactosidase expression vector to
control for transfection efficiency. The data were quantified as
relative fold activation, where 1 represents il1b
( 59/+12)-luciferase reporter activity in the presence of only empty
vectors, corrected for -galactosidase activity. Error
bars represent the standard error from three repetitions.
|
|
Spi-1 and NF-IL6 Directly Interact through Their DNA Binding
Regions, the ETS and bZIP Domains--
It has been shown by a number
of studies that the wHTH domains of Spi-1 and other ETS factors
directly interact with various transcription factors, playing a
possible role in functional cooperativity (17, 18, 30, 36). To
determine whether Spi-1 and NF-IL6 cooperativity in il1b
expression is mediated by protein-protein binding, we performed GST
pull-down protein-interaction assays. The full-length Spi-1 cDNA
and truncated sequences were subcloned into plasmid pGEX-2T to produce
GST fusion constructs. The 35S-labeled NF-IL6 prepared by
in vitro transcription and translation was incubated with
similar amounts of either GST or various GST Spi-1 truncations linked
to Sepharose beads. After incubation, the beads were intensively
washed, and bound proteins were resolved by SDS-PAGE. As shown in Fig.
7A, NF-IL6 binds directly to
full-length Spi-1 (lane 2), but not to the GST control
(lane 1). More specifically, only the DNA binding domain of
Spi-1 (amino acids 171-272) (lane 3) is required to mediate
the interaction with NF-IL6. The GST fusion construct containing amino
acids 202-254 (lane 4) bound to NF-IL6 as well as the
full-length protein. The 202-254 region was further dissected into two
pieces, which were also fused to GST (the 243-254 and 202-242
constructs, lanes 5 and 6). Both of these fusion
proteins were capable of weakly binding to NF-IL6. It is possible that
regions containing both the 2/ 2/ 3 and 3/ 4 (Fig.
5A) structural elements are important in mediating Spi-1 and
NF-IL6 interaction.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 7.
Spi-1 and NF-IL6 interact with each other
through their DNA binding regions. A, equal amounts of
GST and GST-Spi-1 fusion proteins containing various structural
elements of Spi-1, as depicted in Fig. 5A, were prepared and
tested for binding to in vitro translated
35S-labeled full-length NF-IL6 protein by GST pull-down
assay. Numbers above the panel indicate the region of Spi-1
amino acid sequence present in the fusion protein. Quantitation of the
expressed GST fusion proteins was determined by Coomassie Brilliant
Blue staining (data not shown). Lane 7 shows the mobility of
in vitro translated NF-IL6 protein by SDS-PAGE.
B, equal amounts of GST, or GST-wHTH fusion protein
containing the DNA binding domain of Spi-1 (aa 171-272), was incubated
with in vitro translated 35S-labeled NF-IL6,
NF-IL6 Spl ( aa 41-205), or NF-IL6 bZIP ( aa 1-268)
in the GST pull-down assay. C, reciprocal GST pull-down
assay confirms the binding between NF-IL6 bZIP domain and Spi-1 wHTH
domain. The NF-IL6 bZIP domain (aa 269-345) was expressed as a GST
fusion protein and immobilized to glutathione-Sepharose beads. The wHTH
domain of Spi-1 was in vitro translated and labeled with
35S. For B and C, one-fourth of the
input 35S-labeled protein was analyzed by SDS-PAGE as a
control, showing the mobility of in vitro translated
protein.
|
|
To identify sequences within NF-IL6 necessary for interaction with
Spi-1, we prepared in vitro translated
35S-labeled NF-IL6 with amino-terminal deletions and tested
for interaction with GST-Spi-1 171-272 (Fig. 7B). Similar
to the full-length NF-IL6 (lane 2), the mutant
Spl NF-IL6 with the deletion of the region from amino
acids 41-205 binds to the Spi-1 ETS domain (lane 4). It is
noteworthy that deletion of the amino-terminal 268 amino acids of
NF-IL6, leaving only the bZIP DNA binding domain, dramatically increased the binding affinity observed in the GST pull-down assay (lane 6). It was reported that, in the absence of
activation, one of two regulatory elements (RD2, Fig. 4) from rat
NF-IL6 could inhibit DNA binding by intramolecular interaction, whereas
the other element (RD1) similarly inhibited transactivation (28, 29).
Our data suggest that the RD2 domain, specifically the region from aa
206 to 268, may also prevent NF-IL6 from interacting with its cofactors.
In a reciprocal assay, 35S-labeled Spi-1 ETS domain (from
amino acids 171-272) was prepared by in vitro transcription
and translation and incubated with GST-bZIP fusion protein containing
the bZIP region of NF-IL6 from amino acids 269-345. As expected, the
labeled Spi-1 wHTH domain bound strongly to GST-bZIP, but not to GST
alone (Fig. 7C).
 |
DISCUSSION |
The expression of il1b is regulated by two independent
elements, an upstream inducible sequence (the UIS enhancer) and a cell type-specific promoter element (37). Although strong
enhancer-dependent activity depends upon a long promoter
extending from 131 to +12 (13), weaker enhancer-independent activity
can be detected with the shorter 59/+12 promoter. Moreover, we have
recently shown that the Spi-1 binding site located at position
50/ 39 is responsible for mediating transactivation of
il1b expression by cytomegalovirus IE2 protein, which
eliminates the need for the otherwise essential upstream enhancer
(21).
In this report, we have demonstrated that NF-IL6 dramatically
cooperates with Spi-1 to activate the il1b core promoter,
where the Spi-1 binding site, but not the putative NF-IL6 site, is
critical. Although the Spi-1 recognition site is sufficiently important that mutations leading to a complete loss of Spi-1 binding result in a
total loss of promoter activity in the presence of cotransfected Spi-1
and NF-IL6, deletion of the transcription activation domains of Spi-1
results in only a partial loss of its ability to functionally cooperate
with NF-IL6. In contrast, the deletion of the NF-IL6 transactivation
domain (aa 41-205) completely abolishes its ability to synergize with
Spi-1 on the il1b core promoter. Physical interaction between the Spi-1 wHTH and the NF-IL6 bZIP DNA binding domains provides
the basis for our model. In this model, the Spi-1 wHTH domain functions
to recognize a specific site in the il1b core promoter and
tether NF-IL6, which contains an efficient transcription activation
domain, which, unlike those of Spi-1, is able to strongly activate
il1b expression (Fig. 8). This
is distinct from an earlier report of NF-IL6 cooperativity with
glucocorticoid receptor, in which the NF-IL6 played a TAD-independent
and indirect role (38). It should be noted that we could not detect a
reproducible ternary complex (data not shown), involving NF-IL6, Spi-1,
and DNA using either EMSA or a more sensitive GST-based two-hybrid
approach (21), suggesting a tenuous interaction. Others have also
attempted to detect ternary complexes involving NF-IL6 and have failed
(38, 39), supporting this conclusion.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 8.
Proposed cooperative PTT model for activation
of the il1b promoter by Spi-1 and NF-IL6. Spi-1
mainly functions as a DNA-binding protein, tethering NF-IL6 to the
proximity of the transcriptional initiation machinery. Although the
Spi-1 TADs contribute to the cooperativity, they are not as critical as
that of NF-IL6. Also shown is a speculated role for Spi-1 as both a
DNA- and protein-binding factor, which may integrate the
il1b far-upstream inducible enhancer (UIS)
containing two NF-IL6 binding sites to the core promoter through NF-IL6
interaction.
|
|
Our model is supported by two facts. First, cotransfection of NF-IL6
expression vector significantly increased the ability of both
Spi-1 100 (lacking both TBP and Q TADs) and Spi-1 PEST (lacking the
PEST region) to activate the il1b core promoter (Fig. 5).
Second, although the dominant negative NF-IL6 was not able to repress
the Spi-1-independent activity of the il1b core promoter in
NF-IL6-expressing HeLa cells (22), it antagonized the Spi-1-mediated activation of the same promoter in a dose-dependent manner.
This is consistent with the notion that Spi-1 activation of the
il1b core promoter is mediated by NF-IL6 and that the
putative overlapping NF-IL6 site is not functional. GST pull-down
assays demonstrate that both NF-IL6 Spl and the
full-length protein interact with Spi-1 at a similar level (Fig. 7),
implying that NF-IL6 Spl may compete with endogenous
NF-IL6 for interaction with Spi-1. It has been reported that Spi-1
without the TBP and Q TADs can activate transcription by playing an
architectural role in interaction with NF-EM5/Pip/IRF-4 mediated by the
PEST region (40). Recently, we have shown that functional cooperativity
between Spi-1 and the cytomegalovirus IE2 transcription factor does not
require any Spi-1 TADs (including PEST) for activity (21). Our data now
provide a new example in which the Spi-1 wHTH functions both to bind
DNA and to tether a nonviral transcription factor containing a more
potent TAD.
The mechanism by which the il1b UIS is integrated into the
core promoter has always been a puzzle. We have reported that the UIS
sequence between 3134 and 2729 contains two NF-IL6 binding sites
(11, 23). Also we have shown that the 131/ 59, which contains an
additional Spi-1 binding site, is critical for enhancer activity (13).
Our results now suggest the possibility that factors bound to the UIS,
including LIL-Stat, CREB, and NF-IL6 (23), may be tethered to the
proximity of the transcriptional initiation machinery through
NF-IL6-Spi-1 interactions (Fig. 8). However, carefully designed
experiments are needed to confirm this speculation.
In this report, we have shown that NF-IL6, which is abundant in myeloid
cells (41), strongly synergizes with Spi-1 on the il1b core
promoter via PTT (21) in transient transfection assays using
Spi-1-deficient HeLa cells. This suggests that PTT also functions in
IL-1 -producing monocyte/macrophage cells. However, other bZIP family
factors, such as NF-IL6 (C/EBP ) (17), c-Jun (20), as well as
other cellular or viral transcription factors (21, 42, 43), have been
shown to physically interact with Spi-1. It would be interesting to
determine whether other factors, which are also expressed at various
levels over the course of myeloid differentiation, particularly c-Jun
(44-46), C/EBP (17), C/EBP (41), and C/EBP (47), can also
synergize with Spi-1 on the il1b core promoter. Consistent
with this prediction, we have recently demonstrated that the viral
protein HCMV IE2 strongly activates the il1b promoter via
PTT using a similar Spi-1 tether (21).
 |
ACKNOWLEDGEMENTS |
We thank R. Maki and D. G. Tenen for
various Spi-1 expression plasmids, A. C. Webb and B. Choy for
helpful discussions and technical assistance, and E. Chase for
secretarial assistance.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant CA68544 (to P. E. A).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of the individual National Research Service Award.
¶
Present address: Khon Kaen University, Faculty of Dentistry,
Khon Kaen, Thailand 40002.
**
Present address: First Dept. of Internal Medicine, School of
Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807, Japan.

To whom correspondence should be addressed: Harvard Institutes
of Medicine, Rm. 245, 77 Ave. Louis Pasteur, Boston, MA 02115-5727. Tel.: 617-667-0741, Fax: 617-975-5299; E-mail: pauron@caregroup. harvard.edu.
Published, JBC Papers in Press, May 2, 2000, DOI 10.1074/jbc.M000145200
 |
ABBREVIATIONS |
The abbreviations used are:
IL, interleukin;
PMA, phorbol myristate acetate;
bZIP, basic leucine zipper;
wHTH, winged helix-turn-helix;
TAD, transactivation domain;
PTT, protein-tethered transactivation;
GST, glutathione
S-transferase;
PAGE, polyacrylamide gel electrophoresis;
EMSA, electrophoretic mobility shift assay;
TBP, TATA box-binding
protein;
UIS, upstream inducible enhancer;
aa, amino acid(s).
 |
REFERENCES |
| 1.
|
Williams, S. C.,
Cantwell, C. A.,
and Johnson, P. F.
(1991)
Genes Dev.
5,
1553-1567
|
| 2.
|
Akira, S.,
Isshiki, H.,
Sugita, T.,
Tanabe, O.,
Kinoshita, S.,
Nishio, Y.,
Nakajima, T.,
Hirano, T.,
and Kishimoto, T.
(1990)
EMBO J.
9,
1897-1906
|
| 3.
|
Thomassin, H.,
Hamel, D.,
Bernier, D.,
Guertin, M.,
and Belanger, L.
(1992)
Nucleic Acids Res.
20,
3091-3098
|
| 4.
|
Descombes, P.,
Chojkier, M.,
Lichtsteiner, S.,
Falvey, E.,
and Schibler, U.
(1990)
Genes Dev.
4,
1541-1551
|
| 5.
|
Poli, V.,
Mancini, F. P.,
and Cortese, R.
(1990)
Cell
63,
643-653
|
| 6.
|
Chang, C. J.,
Chen, T. T.,
Lei, H. Y.,
Chen, D. S.,
and Lee, S. C.
(1990)
Mol. Cell. Biol.
10,
6642-6653
|
| 7.
|
Birkenmeier, E. H.,
Gwynn, B.,
Howard, S.,
Jerry, J.,
Gordon, J. I.,
Landschulz, W. H.,
and McKnight, S. L.
(1989)
Genes Dev.
3,
1146-1156
|
| 8.
|
Kunsch, C.,
Lang, R. K.,
Rosen, C. A.,
and Shannon, M. F.
(1994)
J. Immunol.
153,
153-164
|
| 9.
|
Lee, Y. H.,
Yano, M.,
Liu, S. Y.,
Matsunaga, E.,
Johnson, P. F.,
and Gonzalez, F. J.
(1994)
Mol. Cell. Biol.
14,
1383-1394
|
| 10.
|
Yamaguchi, Y.,
Nishio, H.,
Kishi, K.,
Ackerman, S. J.,
and Suda, T.
(1999)
Blood
94,
1429-1439
|
| 11.
|
Auron, P. E.,
and Webb, A. C.
(1994)
Eur. Cytokine Netw.
5,
573-592
|
| 12.
|
Zhang, Y.,
and Rom, W. N.
(1993)
Mol. Cell. Biol.
13,
3831-3837
|
| 13.
|
Kominato, Y.,
Galson, D.,
Waterman, W. R.,
Webb, A. C.,
and Auron, P. E.
(1995)
Mol. Cell. Biol.
15,
59-68
|
| 14.
|
Buras, J. A.,
Monks, B. G.,
and Fenton, M. J.
(1994)
J. Immunol.
152,
4444-4454
|
| 15.
|
Petrovick, M. S.,
Hiebert, S. W.,
Friedman, A. D.,
Hetherington, C. J.,
Tenen, D. G.,
and Zhang, D. E.
(1998)
Mol. Cell. Biol.
18,
3915-3925
|
| 16.
|
Oelgeschlager, M.,
Nuchprayoon, I.,
Luscher, B.,
and Friedman, A. D.
(1996)
Mol. Cell. Biol.
16,
4717-4725
|
| 17.
|
Nagulapalli, S.,
Pongubala, J. M.,
and Atchison, M. L.
(1995)
J. Immunol.
155,
4330-4338
|
| 18.
|
Bassuk, A. G.,
and Leiden, J. M.
(1995)
Immunity
3,
223-237
|
| 19.
|
Moulton, K. S.,
Semple, K.,
Wu, H.,
and Glass, C. K.
(1994)
Mol. Cell. Biol.
14,
4408-4418
|
| 20.
|
Behre, G.,
Whitmarsh, A. J.,
Coghlan, M. P.,
Hoang, T.,
Carpenter, C. L.,
Zhang, D. E.,
Davis, R. J.,
and Tenen, D. G.
(1999)
J. Biol. Chem.
274,
4939-4946
|
| 21.
|
Wara-aswapati, N.,
Yang, Z.,
Waterman, W. R.,
Koyama, Y.,
Tetradis, S.,
Choy, B. K.,
Webb, A. C.,
and Auron, P. E.
(1999)
Mol. Cell. Biol.
19,
6803-6814
|
| 22.
|
Galson, D. L.,
Hensold, J. O.,
Bishop, T. R.,
Schalling, M.,
D'Andrea, A. D.,
Jones, C.,
Auron, P. E.,
and Housman, D. E.
(1993)
Mol. Cell. Biol.
13,
2929-2941
|
| 23.
|
Tsukada, J.,
Saito, K.,
Waterman, W. R.,
Webb, A. C.,
and Auron, P. E.
(1994)
Mol. Cell. Biol.
14,
7285-7297
|
| 24.
|
Chittenden, T.,
Livingston, D. M.,
and Kaelin, W. G., Jr.
(1991)
Cell
65,
1073-1082
|
| 25.
|
Clark, B. D.,
Fenton, M. J.,
Rey, H. L.,
Webb, A. C.,
and Auron, P. E.
(1988)
in
Monokines and Other Non-lymphocytic Cytokines
(Powanda, M. C.
, Oppenheim, J. J.
, Kluger, M. J.
, and Denarello, C., eds)
, pp. 47-53, Alan R. Liss, New York
|
| 26.
|
Mink, S.,
Haenig, B.,
and Klempnauer, K. H.
(1997)
Mol. Cell. Biol.
17,
6609-6617
|
| 27.
|
Kowenz-Leutz, E.,
and Leutz, A.
(1999)
Mol. Cell
4,
735-743
|
| 28.
|
Kowenz-Leutz, E.,
Twamley, G.,
Ansieau, S.,
and Leutz, A.
(1994)
Genes Dev.
8,
2781-2791
|
| 29.
|
Williams, S. C.,
Baer, M.,
Dillner, A. J.,
and Johnson, P. F.
(1995)
EMBO J.
14,
3170-3183
|
| 30.
|
Bassuk, A. G.,
Anandappa, R. T.,
and Leiden, J. M.
(1997)
J. Virol.
71,
3563-3573
|
| 31.
|
Yamamoto, H.,
Kihara-Negishi, F.,
Yamada, T.,
Hashimoto, Y.,
and Oikawa, T.
(1999)
Oncogene
18,
1495-1501
|
| 32.
|
Hagemeier, C.,
Bannister, A. J.,
Cook, A.,
and Kouzarides, T.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1580-1584
|
| 33.
|
Brass, A. L.,
Zhu, A. Q.,
and Singh, H.
(1999)
EMBO J.
18,
977-991
|
| 34.
|
Brass, A. L.,
Kehrli, E.,
Eisenbeis, C. F.,
Storb, U.,
and Singh, H.
(1996)
Genes Dev.
10,
2335-2347
|
| 35.
|
Heiland, S.,
and Knippers, R.
(1995)
Mol. Cell. Biol.
15,
6623-6631
|
| 36.
|
Sieweke, M. H.,
Tekotte, H.,
Frampton, J.,
and Graf, T.
(1996)
Cell
85,
49-60
|
| 37.
|
Shirakawa, F.,
Saito, K.,
Bonagura, C. A.,
Galson, D. L.,
Fenton, M. J.,
Webb, A. C.,
and Auron, P. E.
(1993)
Mol. Cell. Biol.
13,
1332-1344
|
| 38.
|
Nishio, Y.,
Isshiki, H.,
Kishimoto, T.,
and Akira, S.
(1993)
Mol. Cell. Biol.
13,
1854-1862
|
| 39.
|
Hocke, G. M.,
Barry, D.,
and Fey, G. H.
(1992)
Mol. Cell. Biol.
12,
2282-2294
|
| 40.
|
Pongubala, J. M.,
and Atchison, M. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
127-132
|
| 41.
|
Scott, L. M.,
Civin, C. I.,
Rorth, P.,
and Friedman, A. D.
(1992)
Blood
80,
1725-1735
|
| 42.
|
Johannsen, E.,
Koh, E.,
Mosialos, G.,
Tong, X.,
Kieff, E.,
and Grossman, S. R.
(1995)
J. Virol.
69,
253-262
|
| 43.
|
Tsukada, J.,
Misago, M.,
Serino, Y.,
Ogawa, R.,
Murakami, S.,
Nakanishi, M.,
Tonai, S.,
Kominato, Y.,
Morimoto, I.,
Auron, P. E.,
and Eto, S.
(1997)
Blood
90,
3142-3153
|
| 44.
|
Lord, K. A.,
Abdollahi, A.,
Hoffman-Liebermann, B.,
and Liebermann, D. A.
(1993)
Mol. Cell. Biol.
13,
841-851
|
| 45.
|
Mollinedo, F.,
and Naranjo, J. R.
(1991)
Eur. J. Biochem.
200,
483-486
|
| 46.
|
Gaynor, R.,
Simon, K.,
and Koeffler, P.
(1991)
Blood
77,
2618-2623
|
| 47.
|
Morosetti, R.,
Park, D. J.,
Chumakov, A. M.,
Grillier, I.,
Shiohara, M.,
Gombart, A. F.,
Nakamaki, T.,
Weinberg, K.,
and Koeffler, H. P.
(1997)
Blood
90,
2591-2600
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Matsuura, J. Tsukada, T. Mizobe, T. Higashi, F. Mouri, R. Tanikawa, A. Yamauchi, M. Hirashima, and Y. Tanaka
Intracellular galectin-9 activates inflammatory cytokines in monocytes.
Genes Cells,
April 1, 2009;
14(4):
511 - 521.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, S. Saccani, H. Shin, and B. S. Nikolajczyk
Dynamic Protein Associations Define Two Phases of IL-1{beta} Transcriptional Activation
J. Immunol.,
July 1, 2008;
181(1):
503 - 512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cortes-Canteli, R. Luna-Medina, M. Sanz-SanCristobal, A. Alvarez-Barrientos, A. Santos, and A. Perez-Castillo
CCAAT/enhancer binding protein {beta} deficiency provides cerebral protection following excitotoxic injury
J. Cell Sci.,
April 15, 2008;
121(8):
1224 - 1234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Woltje, B. Tschoke, V. von Bulow, R. Westenfeld, B. Denecke, S. Graber, and W. Jahnen-Dechent
CCAAT enhancer binding protein beta and hepatocyte nuclear factor 3beta are necessary and sufficient to mediate dexamethasone-induced up-regulation of alpha2HS-glycoprotein/fetuin-A gene expression.
J. Mol. Endocrinol.,
April 1, 2006;
36(2):
261 - 277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Listman, N. Wara-aswapati, J. E. Race, L. W. Blystone, N. Walker-Kopp, Z. Yang, and P. E. Auron
Conserved ETS Domain Arginines Mediate DNA Binding, Nuclear Localization, and a Novel Mode of bZIP Interaction
J. Biol. Chem.,
December 16, 2005;
280(50):
41421 - 41428.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Awomoyi, M. Charurat, A. Marchant, E. N. Miller, J. M. Blackwell, K. P.W.J. McAdam, and M. J. Newport
Polymorphism in IL1B: IL1B--511 association with tuberculosis and decreased lipopolysaccharide-induced IL-1{beta} in IFN-{gamma} primed ex-vivo whole blood assay
Innate Immunity,
October 1, 2005;
11(5):
281 - 286.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Geng, P. Laslo, K. Barton, and C.-R. Wang
Transcriptional Regulation of CD1D1 by Ets Family Transcription Factors
J. Immunol.,
July 15, 2005;
175(2):
1022 - 1029.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Aittomaki, J. Yang, E. W. Scott, M. C. Simon, and O. Silvennoinen
Molecular basis of Stat1 and PU.1 cooperation in cytokine-induced Fc{gamma} receptor I promoter activation
Int. Immunol.,
February 1, 2004;
16(2):
265 - 274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Yoshida, A. Kumar, Y. Koyama, H. Peng, A. Arman, J. A. Boch, and P. E. Auron
Interleukin 1 Activates STAT3/Nuclear Factor-{kappa}B Cross-talk via a Unique TRAF6- and p65-dependent Mechanism
J. Biol. Chem.,
January 16, 2004;
279(3):
1768 - 1776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. K. Cheng, R. L. C. Hoo, B. K. C. Chow, and P. C. K. Leung
Functional Cooperation between Multiple Regulatory Elements in the Untranslated Exon 1 Stimulates the Basal Transcription of the Human GnRH-II Gene
Mol. Endocrinol.,
July 1, 2003;
17(7):
1175 - 1191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. So, J. Rho, D. Jeong, R. Park, D. E. Fisher, M. C. Ostrowski, Y. Choi, and N. Kim
Microphthalmia Transcription Factor and PU.1 Synergistically Induce the Leukocyte Receptor Osteoclast-associated Receptor Gene Expression
J. Biol. Chem.,
June 20, 2003;
278(26):
24209 - 24216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-M. Wang, M.-Z. Lai, and H.-F. Yang-Yen
Interleukin-3 Stimulation of mcl-1 Gene Transcription Involves Activation of the PU.1 Transcription Factor through a p38 Mitogen-Activated Protein Kinase-Dependent Pathway
Mol. Cell. Biol.,
March 15, 2003;
23(6):
1896 - 1909.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Xie, R. Zhong, C. Chen, and S. K. Calderwood
Heat Shock Factor 1 Contains Two Functional Domains That Mediate Transcriptional Repression of the c-fos and c-fms Genes
J. Biol. Chem.,
February 7, 2003;
278(7):
4687 - 4698.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. S. Carl, K. Brown-Steinke, M. J. H. Nicklin, and M. F. Smith Jr.
Toll-like Receptor 2 and 4 (TLR2 and TLR4) Agonists Differentially Regulate Secretory Interleukin-1 Receptor Antagonist Gene Expression in Macrophages
J. Biol. Chem.,
May 10, 2002;
277(20):
17448 - 17456.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Xie, C. Chen, M. A. Stevenson, P. E. Auron, and S. K. Calderwood
Heat Shock Factor 1 Represses Transcription of the IL-1beta Gene through Physical Interaction with the Nuclear Factor of Interleukin 6
J. Biol. Chem.,
March 29, 2002;
277(14):
11802 - 11810.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Toda, J. Tsukada, M. Misago, Y. Kominato, P. E. Auron, and Y. Tanaka
Autocrine Induction of the Human Pro-IL-1{beta} Gene Promoter by IL-1{beta} in Monocytes
J. Immunol.,
February 15, 2002;
168(4):
1984 - 1991.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. B. Riquet, L. Tan, B. K. Choy, M. Osaki, G. Karsenty, T. F. Osborne, P. E. Auron, and M. B. Goldring
YY1 Is a Positive Regulator of Transcription of the Col1a1 Gene
J. Biol. Chem.,
October 12, 2001;
276(42):
38665 - 38672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Saunders, L. Sansores-Garcia, D. W. Gilroy, and K. K. Wu
Selective Suppression of CCAAT/Enhancer-binding Protein beta Binding and Cyclooxygenase-2 Promoter Activity by Sodium Salicylate in Quiescent Human Fibroblasts
J. Biol. Chem.,
May 25, 2001;
276(22):
18897 - 18904.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|